As India's Exports Take Off, Building Brand India Will Be Key Focus, Says Government
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Building "Brand India" to boost the pharmaceutical trade will be a key priority for the Indian government as estimates suggest that exports of finished products and raw materials from India could more than double to $20 billion by 2015
You may also be interested in...
Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania
TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania
With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub
MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries
India Proposes Big Push To Pharma Manufacturing And Research; Talks On With Multinational Companies For Vaccine Development Center
MUMBAI - The Indian government is moving swiftly on a series of new initiatives that seek to position India as a country of choice for big pharmaceutical companies looking to establish research centers and build manufacturing facilities. An outlay of $1 to $2 billion will be made every year through 2020 for the comprehensive action plan, if implemented